Publicaciones en las que colabora con Salvador Martín Algarra (30)

2021

  1. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 6, pp. 586-598

2020

  1. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

    Science Translational Medicine, Vol. 12, Núm. 565

2018

  1. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319

2017

  1. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

    Annals of Oncology, Vol. 28, Núm. 8, pp. 1988-1995

2015

  1. Enhancing T cell performance against cancer in combination treatment strategies

    Cancer Drug Discovery and Development (Humana Press Inc.), pp. 245-258

  2. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice

    Cancer Research, Vol. 75, Núm. 17, pp. 3466-3478

2014

  1. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins

    Clinical Cancer Research, Vol. 20, Núm. 22, pp. 5697-5707

2012

  1. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy

    Journal of Immunology, Vol. 189, Núm. 7, pp. 3299-3310

  2. Immunostimulatory monoclonal antibodies for melanoma treatment

    Emerging Therapeutics for Melanoma (Future Medicine Ltd.), pp. 81-91

2011

  1. Assessment of epidermal growth factor receptor and krasmutation status in cytological stained smears of non-small celllung cancer patients: Correlation with clinical outcomes

    Oncologist, Vol. 16, Núm. 6, pp. 877-885

  2. Determinants of toxicity, patterns of failure, and outcome among adult patients with soft tissue sarcomas of the extremity and superficial trunk treated with greater than conventional doses of perioperative high-dose-rate brachytherapy and external beam radiotherapy

    International Journal of Radiation Oncology Biology Physics, Vol. 81, Núm. 4

  3. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients

    Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142

  4. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo

    International Journal of Cancer, Vol. 129, Núm. 2, pp. 374-386

2009

  1. Nonreferral of possible soft tissue sarcomas in adults: A dangerous omission in policy

    Sarcoma, Vol. 2009

2008

  1. Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma

    Oncology, Vol. 74, Núm. 1-2, pp. 12-16

  2. Soft tissue sarcoma: Can a rescue procedure be performed when the first surgery was unsuccessful?

    Revista Espanola de Cirugia Ortopedica y Traumatologia, Vol. 52, Núm. 1, pp. 21-26

2007

  1. Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab

    Clinical and Translational Oncology, Vol. 9, Núm. 2, pp. 119-120

2005

  1. Perioperative high-dose-rate brachytherapy in soft tissue sarcomas of the extremity and superficial trunk in adults: Initial results of a pilot study

    Brachytherapy, Vol. 4, Núm. 4, pp. 264-270

2004

  1. A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients

    Bone Marrow Transplantation, Vol. 33, Núm. 5, pp. 499-502

  2. ERK 1/2 is activated in non-small-cell lung cancer and associated with advanced tumours

    British Journal of Cancer, Vol. 90, Núm. 5, pp. 1047-1052